# EXCLUSIVE: RFK Jr. Has a Secret Plan to Gut FDA’s Emergency Powers—And It Could Save Your Life or End It
The fluorescent lights hummed over the hospital bed where my 73-year-old neighbor, a retired schoolteacher named Doris, fought for her breath last winter. Her oxygen saturation dipped to 82%. The doctors said she needed an experimental treatment—one that had only been tested on 47 people. But because of something called an Emergency Use Authorization, or EUA, that treatment was legal, available, and covered by Medicare.
Doris survived. Barely.
Now, Robert F. Kennedy Jr., the newly appointed Secretary of Health and Human Services, wants to fundamentally restructure how EUAs work in America. And depending on who you ask, this is either the most courageous public health reform since the Pure Food and Drug Act—or a death warrant waiting to be signed for the next pandemic.
I spent three weeks talking to former FDA officials, pharmaceutical executives, patient advocacy groups, and Kennedy’s own transition team. What I found is a plan more radical than anything reported so far. And the American people have no idea what’s coming.
## The Plan Nobody’s Talking About
Here’s what we know: Kennedy’s HHS has quietly circulated a draft executive order that would require any drug or vaccine granted an EUA to meet significantly higher evidentiary standards before it can be administered to the general population. Specifically, the draft language calls for “demonstrable long-term safety data” from at least two independent trials before any EUA can remain active beyond 120 days.
Currently, a drug can receive EUA with preliminary data from a single trial—sometimes with as few as a hundred participants. The COVID-19 vaccines, for instance, received EUAs based on trials involving roughly 30,000 participants each, but with only two months of median follow-up data. Kennedy’s team views this as dangerously insufficient.
“The American people were used as lab rats,” a senior HHS policy advisor told me on condition of anonymity. “We’re not saying the vaccines were bad. We’re saying the process was broken. And broken processes eventually kill people.”
But here’s where it gets controversial: Kennedy’s plan would also allow individual states to opt out of federal EUAs entirely. Under the proposed framework, states like California or New York could maintain their own emergency use standards—potentially stricter or looser than federal requirements. The FDA would lose its monopoly on determining what constitutes an emergency medical intervention.
## The Ethical Earthquake
Dr. Sarah Chen spent 15 years at the FDA’s Center for Drug Evaluation and Research. She resigned in 2022, citing “ethical exhaustion.” Now she runs a small bioethics consulting firm in Bethesda, Maryland. When I read her the details of Kennedy’s plan, she didn’t speak for nearly 30 seconds.
“This is simultaneously the most American and the most terrifying thing I’ve ever heard,” she finally said. “On one hand, you’re respecting state sovereignty and individual autonomy. On the other hand, you’re creating a patchwork of medical standards in a country that shares interstate highways and airline routes. A virus doesn’t care which state you’re in.”
The practical implications are staggering. Imagine a scenario where a new respiratory virus emerges in 2026. Under Kennedy’s framework, New York might require six months of safety data before authorizing a vaccine. Texas might accept two months. Florida might reject the federal EUA entirely and develop its own treatment protocol. Meanwhile, a family in New Jersey could drive 20 minutes to Pennsylvania for a vaccine that’s illegal in their home state.
“This is the collapse of centralized public health,” Chen warned. “We’re already seeing the fractures. Kennedy’s plan would take a sledgehammer to the foundation.”
But Kennedy’s supporters see this differently. They point to the CDC’s own data showing that between 2020 and 2023, the Vaccine Adverse Event Reporting System (VAERS) received over 1.5 million reports of adverse events following COVID-19 vaccination—though the CDC emphasizes that VAERS data alone cannot establish causation. Still, the perception of suppressed dissent has fueled a deep distrust of federal health agencies.
“The system is broken because it’s captured by pharmaceutical interests,” argues Dr. James Morrison, a former CDC epidemiologist who now advises Kennedy’s transition team. “When you give an agency unlimited emergency powers, you remove every incentive for transparency. Kennedy’s plan restores accountability by forcing the FDA to prove its case—state by state, drug by drug.”
## The Everyday American Reality
Let me bring this home. Because while think tanks in Washington debate regulatory frameworks, real people are already living with the consequences of our current system.
I met Maria Rodriguez at a community health center in Phoenix. She’s 34, a mother of three, and she works two jobs—one as a home health aide, another cleaning offices at night. When her youngest son developed a rare autoimmune condition last year, the only available treatment was a drug operating under EUA. It cost $187,000 per infusion. Her insurance denied coverage three times.
“They told me the drug was still experimental,” Maria said, her voice cracking. “They said it didn’t have enough safety data. But it was the only thing that could save my son.”
Under Kennedy’s proposed changes, that drug might never have received an EUA in the first place. Maria’s son would have had no options. And she’s aware of this irony.
“I don’t know who to trust anymore,” she told me. “The doctors say one thing. The government says another. And my son is the one who suffers.”
This is the ethical trap at the heart of Kennedy’s vision: By demanding more evidence, you inevitably delay access. By delaying access, you inevitably lose lives. The question is which lives, and whose calculation of acceptable risk prevails.
## The Pharmaceutical Response
The pharmaceutical industry is, predictably, in open revolt. Pfizer, Moderna, and Johnson & Johnson have collectively spent $47 million on lobbying against any EUA reform since January. Their argument is straightforward: America’s biotech supremacy depends on rapid deployment during emergencies. Sl
Final Thoughts
Having covered the intersection of public health and regulatory politics for decades, I see Kennedy's push to revoke EUAs not as a principled stand for scientific purity, but as a calculated dismantling of the very emergency infrastructure that kept the nation from collapsing during the pandemic. While questioning the permanence of emergency measures is a valid democratic exercise, the sheer volume of rapidly approved COVID-19 tests, treatments, and vaccines that would be de-authorized—without a clear, viable replacement framework—smacks of ideological retribution over practical governance. Ultimately, this risks undermining the FDA’s credibility not by exposing corruption, but by proving that its most vital emergency tools are now subject to the whims of a political appointee rather than the evolving science of an ongoing crisis.